Elcatonin injections suppress systemic bone resorption without affecting cortical bone regeneration after drill-hole injuries in mice.
It is assumed that there are systemic changes in mineral metabolism during fracture healing that may cause a predisposition to sequential fractures in osteoporotic patients who suffered from previous fractures. Initial therapies for patients with osteoporotic fractures are important to prevent disabilities in daily life consequent to bone and muscle atrophies, and sequential fractures, although systemic and local bone metabolism during fracture healing have not been well understood. We evaluated the effects of bone injury and elcatonin injection as an initial therapy on systemic and local bone turnover and bone wound healing. Two drill holes were made in the diaphysis of the left femur and tibia of 12-week-old male C57BL/6J mice. They were treated with three doses of elcatonin or a vehicle thrice a week until the end of the 28-day experiment. Urinary crosslinked C-telopeptide of type I collagen (CTX) increased and the bone mineral densities (BMDs) in the lumbar vertebrae decreased in the vehicle-treated mice. Elcatonin injection prevented increases in urinary CTX and reduction of the BMDs. In the noninjured femoral metaphysis, osteoclast surface increased until day 28, whereas elcatonin suppressed it. In the fracture site, elcatonin facilitated osteoblast proliferation and did not delay the healing of the bone defect. Bone injuries accelerated bone turnover systemically and locally, and the elcatonin injections suppressed the systemic acceleration of bone resorption without a delay of filling regenerated cortical bone in the bone defect.
Katae
Yuji
Y
Department of Orthopaedic Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Kitakyushu, 807-8555, Japan.
Tanaka
Shinya
S
Sakai
Akinori
A
Nagashima
Masato
M
Hirasawa
Hideyuki
H
Nakamura
Toshitaka
T
D015502:Absorptiometry, Photon; D000818:Animals; D015415:Biomarkers / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001861:Bone Regeneration / Q000187:drug effects* / Q000502:physiology; D001862:Bone Resorption / Q000188:drug therapy* / Q000378:metabolism; D002116:Calcitonin / Q000031:analogs & derivatives* / Q000494:pharmacology; D024042:Collagen Type I / Q000235:genetics / Q000378:metabolism / Q000652:urine; D000090602:Collagen Type I, alpha 1 Chain; D004195:Disease Models, Animal; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000293:injuries; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D015675:Osteocalcin / Q000235:genetics / Q000378:metabolism; D010455:Peptides / Q000652:urine; D012333:RNA, Messenger / Q000378:metabolism; D014945:Wound Healing / Q000187:drug effects
D015415:Biomarkers; D050071:Bone Density Conservation Agents; D024042:Collagen Type I; D000090602:Collagen Type I, alpha 1 Chain; D010455:Peptides; D012333:RNA, Messenger; C052929:collagen type I trimeric cross-linked peptide; D015675:Osteocalcin; D002116:Calcitonin; C012755:elcatonin